CYCC - Cyclacel Pharmaceuticals Inc Stock Price, Fair Value and News

1.83USD+0.08 (+4.57%)Market Closed

Market Summary

USD1.83+0.08

Market Closed

4.57%

CYCC Stock Price

View Fullscreen

CYCC RSI Chart

CYCC Valuation

Market Cap

2.3M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

5.49

EV/EBITDA

0.04

Price/Free Cashflow

-0.14

CYCC Price/Sales (Trailing)

CYCC Profitability

EBT Margin

-6083.57%

Return on Equity

-3.7K%

Return on Assets

-256.16%

Free Cashflow Yield

-698.67%

CYCC Fundamentals

CYCC Revenue

Revenue (TTM)

420.0K

Rev. Growth (Qtr)

93.75%

CYCC Earnings

Earnings (TTM)

-22.6M

Earnings Growth (Yr)

28.95%

Earnings Growth (Qtr)

12.62%

Breaking Down CYCC Revenue

Last 7 days

11.5%

Last 30 days

-20.1%

Last 90 days

-19.0%

Trailing 12 Months

-82.0%

How does CYCC drawdown profile look like?

CYCC Financial Health

Current Ratio

0.91

CYCC Investor Care

Shares Dilution (1Y)

57.70%

Diluted EPS (TTM)

-26.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	420.0K
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	150.0K
2016	1.6M	1.5M	987.0K	843.0K
2015	1.9M	1.8M	1.8M	1.9M
2014	1.3M	1.4M	1.8M	1.7M
2013	281.0K	519.0K	790.0K	1.1M
2012	668.0K	526.0K	400.0K	230.0K
2011	258.8K	405.5K	552.3K	699.0K
2010	0	0	0	112.0K
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cyclacel Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 29, 2024	schwartz brian	acquired	-	-	12,500	interim chief medical officer
Dec 21, 2023	mcbarron paul	bought	6,252	3.315	1,886	see remarks
Dec 21, 2023	rombotis spiro george	bought	20,122	3.315	6,070	president and ceo
Jun 30, 2023	ferguson kenneth m.	acquired	-	-	21,219	-
Jun 30, 2023	walker karin l	acquired	-	-	21,219	-
Jun 30, 2023	spiegel robert j.	acquired	-	-	21,219	-
Jun 30, 2023	schwartz brian	acquired	-	-	21,219	-
Jun 30, 2023	henney christopher s	acquired	-	-	21,219	-
Jun 30, 2023	barker sam l	acquired	-	-	21,219	-
Jan 31, 2023	kirschbaum mark	acquired	-	-	31,200	chief medical officer

Which funds bought or sold CYCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	450	3,420	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-30,841	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	new	-	35.00	35.00	-%
Feb 14, 2024	Point72 Asset Management, L.P.	sold off	-100	-81,581	-	-%
Feb 14, 2024	Point72 Asset Management, L.P.	new	-	40,939	40,939	-%
Feb 14, 2024	CITADEL ADVISORS LLC	sold off	-100	-10,669	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-5,826	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-9,979	-	-%
Feb 14, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-10,073	-	-%
Feb 14, 2024	Altium Capital Management LP	new	-	101,412	101,412	0.07%

Are Funds Buying or Selling CYCC?

Are funds buying CYCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYCC

No. of Funds

Unveiling Cyclacel Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	dellora investments lp	0%	0	SC 13G/A
Feb 14, 2024	schonfeld strategic advisors llc	0.18%	1,900	SC 13G/A
Feb 13, 2024	altium capital management lp	4.99%	37,982	SC 13G/A
Feb 07, 2024	acorn bioventures, l.p.	-	0	SC 13G/A
Jan 10, 2024	altium capital management lp	8.0%	82,032	SC 13G
Jan 04, 2024	lind global fund ii lp	9.9%	102,250	SC 13G
Feb 14, 2023	schonfeld strategic advisors llc	6.14%	770,400	SC 13G
Feb 13, 2023	dellora investments lp	5.2%	648,752	SC 13G/A
Feb 06, 2023	sphera funds management ltd.	1.99%	250,000	SC 13G/A
Jan 26, 2023	acorn bioventures, l.p.	9.99%	2,815,146	SC 13G/A

Recent SEC filings of Cyclacel Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	S-1/A	Initial Public Offering
Mar 28, 2024	8-K	Current Report
Mar 22, 2024	S-1	Initial Public Offering
Mar 21, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	424B3	Prospectus Filed
Feb 13, 2024	EFFECT	EFFECT
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Cyclacel Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-0.89%	-25.81%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-3.94%	-8.31%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-12.98%	-52.88%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	7.90%	326.47%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-13.94%	-3.10%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	63.30%	36.92%	-0.25	2.14	-13.45%	66.37%

Cyclacel Pharmaceuticals Inc News

Latest updates

Cyclacel Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	93.8%	31,000	16,000	373,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	3,168,000	2,572,000	2,472,000	2,424,000	2,793,500	2,348,000	2,337,000	2,204,000	2,615,000
Operating Expenses	-21.4%	5,391,000	6,861,000	6,302,000	7,319,000	8,845,000	-	-	-	-	-	-	-	-	-	-	-	-	-	2,337,000	2,204,000	2,615,500
S&GA Expenses	15.3%	1,873,000	1,625,000	1,575,000	1,645,000	2,143,000	-	-	-	-	-	-	-	1,753,000	1,497,000	1,309,000	1,318,000	1,363,000	1,285,000	1,184,000	1,192,000	1,473,500
R&D Expenses	-32.8%	3,518,000	5,236,000	4,727,000	5,674,000	6,702,000	-	-	-	-	-	-	-	1,415,000	1,075,000	1,163,000	1,106,000	1,430,500	1,063,000	1,153,000	1,012,000	1,142,000
EBITDA Margin	-Infinity%	-60.76	-	-186	-182	-170	-152	-149	-152	-145	-125	-104	-79.99	-62.32	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56,000	79,000	93,000
Income Taxes	36.8%	-422,000	-668,000	-586,000	-1,320,000	-1,581,000	-	-	-	-	-	-	-	-378,500	-281,000	-286,000	-290,000	-448,000	-273,000	-307,000	-268,000	-352,000
Earnings Before Taxes	15.0%	-5,693,000	-6,700,000	-6,034,000	-7,124,000	-9,000,000	-	-	-	-	-	-	-	-3,182,000	-2,537,000	-2,452,000	-1,510,000	-2,752,500	-2,174,000	-2,090,000	-2,110,000	-2,370,500
EBT Margin	-Infinity%	-60.84	-	-188	-185	-172	-154	-151	-155	-147	-127	-106	-82.24	-64.54	-	-	-	-	-	-	-	-
Net Income	12.6%	-5,271,000	-6,032,000	-5,448,000	-5,804,000	-7,419,000	-	-	-	-	-	-	-	-2,803,500	-2,256,000	-2,166,000	-1,220,000	-2,304,500	-1,901,000	-1,783,000	-1,842,000	-2,018,500
Net Income Margin	-Infinity%	-53.70	-	-158	-152	-141	-125	-123	-127	-123	-107	-91.10	-71.36	-56.30	-	-	-	-	-	-	-	-
Free Cashflow	3.1%	-3,910,000	-4,036,000	-1,305,000	-6,867,000	-5,169,000	-6,968,000	-1,918,000	-6,779,000	-4,551,000	-6,219,000	-4,153,000	-3,644,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-29.5%	9.00	12.00	17.00	23.00	28.00	32.00	36.00	40.00	43.00	45.00	46.00	52.00	37.00	27.00	29.00	13.00	15.00	17.00	19.00	22.00	20.00
Current Assets	-33.0%	7.00	11.00	15.00	19.00	24.00	28.00	32.00	37.00	41.00	43.00	46.00	50.00	35.00	26.00	28.00	12.00	14.00	16.00	18.00	20.00	20.00
Cash Equivalents	-42.7%	3.00	6.00	10.00	11.00	18.00	24.00	29.00	30.00	37.00	40.00	44.00	48.00	33.00	23.00	25.00	9.00	12.00	13.00	15.00	18.00	18.00
Net PPE	-43.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	0.0%	8.00	8.00	7.00	8.00	8.00	5.00	5.00	6.00	5.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00	5.00
Current Liabilities	0.2%	8.00	8.00	7.00	7.00	8.00	4.00	5.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	4.00
Shareholder's Equity	-85.9%	1.00	4.00	7.00	11.00	16.00	22.00	30.00	34.00	38.00	42.00	43.00	48.00	33.00	24.00	27.00	10.00	12.00	14.00	16.00	18.00	15.00
Retained Earnings	-1.3%	-428	-423	-416	-411	-405	-398	-393	-388	-384	-379	-374	-369	-366	-363	-361	-358	-357	-355	-353	-351	-349
Additional Paid-In Capital	0.3%	430	428	425	423	423	423	424	423	423	422	419	418	400	389	389	370	370	370	370	370	366
Shares Outstanding	25.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	6.00	-	-	-	11.00	-	-	-	55.00	-	-	-	23.00	-	-	-	9.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.1%	-3,910	-4,036	-1,305	-6,861	-5,169	-6,968	-1,915	-6,775	-4,549	-6,210	-4,215	-3,566	-1,152	-2,129	-1,846	-2,807	-1,117	-2,011	-2,635	-3,684	-2,036
Share Based Compensation	-17.6%	322	391	359	401	387	389	350	380	304	320	278	255	141	113	85.00	91.00	105	183	93.00	85.00	76.00
Cashflow From Investing	-	-	-	-	-6.00	-	-	-3.00	-4.00	-2.00	-9.00	62.00	-78.00	-42.00	-50.00	-	-4.00	6.00	-4.00	-1.00	27.00	-6.00
Cashflow From Financing	2098.0%	999	-50.00	-51.00	-50.00	42.00	1,532	1,474	-50.00	887	2,904	-51.00	17,997	11,348	-50.00	18,256	-50.00	-50.00	-57.00	-101	4,056	580

CYCC Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS) - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Revenues	$ 420,000	$ 0
Operating expenses:
Research and development	19,155,000	20,274,000
General and administrative	6,718,000	7,382,000
Total operating expenses	25,873,000	27,656,000
Operating loss	(25,453,000)	(27,656,000)
Other income (expense):
Foreign exchange gains (losses)	(414,000)	233,000
Interest income	266,000	210,000
Other income (expense), net	50,000	1,298,000
Total other income (expense), net	(98,000)	1,741,000
Loss before taxes	(25,551,000)	(25,915,000)
Income tax benefit	2,996,000	4,717,000
Net loss	(22,555,000)	(21,198,000)
Dividend on convertible exchangeable preferred shares	(201,000)	(201,000)
Net loss applicable to common shareholders	$ (22,756,000)	$ (21,399,000)
Basic and diluted earnings per common share:
Net loss per share - diluted		$ (27.24)
Redeemable common shareholders
Other income (expense):
Net loss applicable to common shareholders		$ (2,527,000)
Basic and diluted earnings per common share:
Net loss per share - basic	$ 0	$ (27.24)
Net loss per share - diluted	$ 0.00	$ (27.24)
Common Stock
Other income (expense):
Net loss applicable to common shareholders	$ (22,756,000)	$ (18,872,000)
Basic and diluted earnings per common share:
Net loss per share - basic	$ (26.75)	$ (28.70)
Net loss per share - diluted	$ (26.75)	$ (28.70)

CYCC Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,378	$ 18,345
Prepaid expenses and other current assets	4,066	6,066
Total current assets	7,444	24,411
Property and equipment, net	9	32
Right-of-use lease asset	93	142
Non-current deposits	1,259	3,465
Total assets	8,805	28,050
Current liabilities:
Accounts payable	3,543	2,561
Accrued and other current liabilities	4,618	4,950
Total current liabilities	8,161	7,511
Lease liability	37	106
Total liabilities	8,198	7,617
Redeemable common stock, $0.001 par value; 0 shares issued and outstanding at December 31, 2023 and 207,807 shares issued and outstanding at December 31, 2022 (Note 11)	0	4,494
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022; 1,058,892 shares issued and outstanding at December 31, 2023 and 628,139 shares issued and outstanding at December 31, 2022	1	1
Additional paid-in capital	429,796	422,981
Accumulated other comprehensive loss	(908)	(1,316)
Accumulated deficit	(428,282)	(405,727)
Total stockholders' equity	607	15,939
Total liabilities and stockholders' equity	8,805	28,050
6% convertible exchangeable preferred stock
Stockholders' equity:
Preferred stock, value	0	0
Series A Convertible Preferred Stock
Stockholders' equity:
Preferred stock, value	0	0
Series B Convertible Preferred Stock
Stockholders' equity:
Preferred stock, value	$ 0	$ 0

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CEO	Mr. Spiro George Rombotis
WEBSITE	cyclacel.com
INDUSTRY	Biotechnology

Cyclacel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Cyclacel Pharmaceuticals Inc? What does CYCC stand for in stocks?

CYCC is the stock ticker symbol of Cyclacel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclacel Pharmaceuticals Inc (CYCC)?

As of Mon Apr 22 2024, market cap of Cyclacel Pharmaceuticals Inc is 2.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYCC stock?

You can check CYCC's fair value in chart for subscribers.

What is the fair value of CYCC stock?

You can check CYCC's fair value in chart for subscribers. The fair value of Cyclacel Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cyclacel Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cyclacel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CYCC is over valued or under valued. Whether Cyclacel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cyclacel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCC.

What is Cyclacel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, CYCC's PE ratio (Price to Earnings) is -0.1 and Price to Sales (PS) ratio is 5.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cyclacel Pharmaceuticals Inc's stock?

In the past 10 years, Cyclacel Pharmaceuticals Inc has provided -0.587 (multiply by 100 for percentage) rate of return.